Company Filing History:
Years Active: 2008-2012
Title: Mark Richard Ashton: Innovator in CRTH2-Mediated Treatments
Introduction
Mark Richard Ashton is a notable inventor based in Abingdon, GB. He has made significant contributions to the field of medical treatments, particularly in addressing CRTH2-mediated diseases. With a total of nine patents to his name, Ashton's work has the potential to impact the treatment of various inflammatory conditions.
Latest Patents
Ashton's latest patents focus on the treatment of CRTH2-mediated diseases and conditions. His inventions provide indole derivatives that antagonize prostaglandin D, which can be utilized to treat inflammatory diseases mediated by this compound. This innovative approach highlights his commitment to advancing medical science and improving patient outcomes.
Career Highlights
Throughout his career, Ashton has worked with several prominent companies, including Oxagen Limited and Asterand UK Limited. His experience in these organizations has allowed him to develop and refine his inventions, contributing to the advancement of medical treatments.
Collaborations
Ashton has collaborated with notable professionals in his field, including Edward Andrew Boyd and David Middlemiss. These partnerships have likely enriched his work and fostered innovation in the treatments he has developed.
Conclusion
Mark Richard Ashton is a distinguished inventor whose work in CRTH2-mediated treatments showcases his dedication to medical innovation. His contributions have the potential to significantly improve the lives of individuals suffering from inflammatory diseases.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.